Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Journal of Cosmetic Dermatology · 2026
DOI: 10.1111/jocd.70701 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2026. Verfasst von Rahman Syed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Swat Medical College, Swat, Pakistan. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Superficial Musculoaponeurotic System, Cosmetic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Platysma prominence (PP) is a common aesthetic concern associated with aging, leading to visible neck bands and loss of jawline definition. OnabotulinumtoxinA has emerged as a minimally invasive treatment; however, data from randomized controlled trials (RCTs) remain fragmented.
Aims
To systematically evaluate the efficacy and safety of onabotulinumtoxinA for treating moderate to severe PP through meta‐analysis of RCTs.
Methods
PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception to March 2025 for RCTs comparing onabotulinumtoxinA with placebo in adults with PP. Two reviewers independently extracted data and assessed bias using the Cochrane RoB 2.0 tool. The primary outcomes were ≥ 1‐grade and ≥ 2‐grade improvement on the Clinician (C‐APPS) and Participant (P‐APPS) Allergan Platysma Prominence Scales. Secondary outcomes included patient satisfaction and treatment‐emergent adverse events (TEAEs). Random‐effects meta‐analysis was used to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs).
Results
Three RCTs ( n = 912) were included. OnabotulinumtoxinA significantly increased ≥ 1‐grade (RR = 4.11; 95% CI, 3.60–4.69) and ≥ 2‐grade (RR = 1.83; 95% CI, 1.54–2.17) improvements compared to placebo. Patient satisfaction was higher in the treatment group (RR = 5.55; 95% CI, 4.15–7.43). The incidence of TEAEs was similar between groups (RR = 0.95; 95% CI, 0.76–1.20), with most being mild and transient.
Conclusions
OnabotulinumtoxinA is an effective and well‐tolerated minimally invasive option for improving platysma prominence, offering significant aesthetic and patient‐reported benefits without increasing adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Swat Medical College, Swat, Pakistan.
- Department of Internal Medicine, Saidu Medical College, Swat, Pakistan.
- Fatima College of Health Sciences, Al Ain, UAE.
- Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK.
Zitieren
APA
Syed, R., Khan, A. A., Shah, S., Khan, A., Idrees, M., Ali, M., Al Sinani, M., & Al Maqbali, M. (2026). Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70701
Vancouver
Syed R, Khan AA, Shah S, Khan A, Idrees M, Ali M, et al. Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Cosmetic Dermatology. 2026. doi:10.1111/jocd.70701
BibTeX
@article{Syed2026,
author = {Syed, Rahman and Khan, Ameer Afzal and Shah, Suleman and Khan, Anfal and Idrees, Mohammad and Ali, Mohsin and Al Sinani, Mohammed and Al Maqbali, Mohammed},
title = {Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
doi = {10.1111/jocd.70701}
}
EUVIMED